Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,873.00    21.50 (1.16%)
Bid:
1,872.00
Ask:
1,873.00
Spread: 1.00 (0.053%)
Market Cap: £75.12b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

13 Oct 2022 12:46

RNS Number : 8297C
GSK PLC
13 October 2022
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

729

£13.2260

607

 

£13.2260

908

d)

Aggregated information

 

 

Aggregated volume Price

 

2,244

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I Mackay

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

492

£13.2260

420

£13.2260

628

d)

Aggregated information

 

 

Aggregated volume Price

 

1,540

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 6 October 2022 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$30.0000

418

$30.0000

316

$30.0000

500

d)

Aggregated information

 

 

Aggregated volume Price

 

1,234

$30.0000

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

 

b)

Position/status

President, Vaccines and Global Health

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

230

£13.2260

133

£13.2260

154

d)

Aggregated information

 

 

Aggregated volume Price

 

517

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

94

£13.2260

88

£13.2260

142

d)

Aggregated information

 

 

Aggregated volume Price

 

324

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

135

£13.2260

106

£13.2260

175

d)

Aggregated information

 

 

Aggregated volume Price

 

416

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

57

£13.2260

53

£13.2260

81

d)

Aggregated information

 

 

Aggregated volume Price

 

191

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

220

£13.2260

164

£13.2260

298

d)

Aggregated information

 

 

Aggregated volume Price

 

682

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 6 October 2022 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$30.0000

30

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

 

 

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

President Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

161

£13.2260

129

£13.2260

198

d)

Aggregated information

 

 

Aggregated volume Price

 

488

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

114

£13.2260

97

£13.2260

179

d)

Aggregated information

 

 

Aggregated volume Price

 

390

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

93

£13.2260

75

£13.2260

124

d)

Aggregated information

 

 

Aggregated volume Price

292

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO, ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.2260

155

£13.2260

131

d)

Aggregated information

 

 

Aggregated volume Price

 

286

£13.2260

e)

Date of the transaction

2022-10-10

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFSFFDEESELS
Date   Source Headline
1st Jun 20263:00 pmRNSTotal Voting Rights
1st Jun 20263:00 pmRNSTransaction in Own Shares
28th May 20269:30 amRNSPositive Phase 3 data for bepirovirsen
27th May 20263:30 pmRNSDirector/PDMR Shareholding
26th May 20263:00 pmRNSAdmission to Trading
26th May 20263:00 pmRNSTransaction in Own Shares
22nd May 202610:30 amRNSQ2 2026 Results Date Confirmed - 28 July 2026
20th May 20263:30 pmRNSDirector/PDMR Shareholding
19th May 20263:30 pmRNSDirector/PDMR Shareholding
18th May 20263:00 pmRNSTransaction in Own Shares
18th May 20267:00 amRNSJapan MHLW approves Arexvy for adults 18-49 AIR
14th May 20263:30 pmRNSDirector/PDMR Shareholding
11th May 20263:30 pmRNSDirector/PDMR Shareholding
11th May 20267:05 amRNSCollaboration with CTTQ for bepirovirsen
11th May 20267:00 amRNSGSK - final tranche of share buyback programme
6th May 20266:22 pmRNSResult of AGM
5th May 20263:30 pmRNSDirector/PDMR Shareholding
1st May 20263:00 pmRNSHolding(s) in Company
1st May 20263:00 pmRNSTotal Voting Rights
29th Apr 20263:30 pmRNSDirector/PDMR Shareholding
29th Apr 20267:00 amRNS1st Quarter Results
28th Apr 20263:30 pmRNSDirector/PDMR Shareholding
28th Apr 20267:00 amRNSBepirovirsen priority review US filing acceptance
27th Apr 202612:00 pmRNSEfimosfermin granted US/EU regulatory designations
27th Apr 20267:00 amRNSTESARO update on AnaptysBio Inc. litigation
24th Apr 20263:30 pmRNSDirector/PDMR Shareholding
23rd Apr 20267:00 amRNSTransaction in Own Shares
22nd Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20263:30 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSBlenrep approved in China for 2L+ multiple myeloma
20th Apr 20267:00 amRNSTransaction in Own Shares
17th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20263:30 pmRNSDirector/PDMR Shareholding
16th Apr 20267:00 amRNSTransaction in Own Shares
15th Apr 20267:12 amRNSGSK completes acquisition of 35Pharma Inc.
15th Apr 20267:00 amRNSTransaction in Own Shares
14th Apr 20263:30 pmRNSDirector/PDMR Shareholding
14th Apr 20267:00 amRNSTransaction in Own Shares
13th Apr 20263:30 pmRNSDirector/PDMR Shareholding
13th Apr 20267:00 amRNSTransaction in Own Shares
13th Apr 20267:00 amRNSGSK presents positive data for BEHOLD 1 B7 H4 ADC
10th Apr 20263:30 pmRNSDirector/PDMR Shareholding
10th Apr 20267:00 amRNSTransaction in Own Shares
9th Apr 20263:30 pmRNSDirector/PDMR Shareholding
9th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSExdensur approved for CRSwNP in China
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.